Welcome to our dedicated page for Telomir Pharms SEC filings (Ticker: TELO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Telomir Pharmaceuticals, Inc. (NASDAQ: TELO) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, offering a structured view of how this preclinical-stage biotechnology company reports its progress and corporate events. Telomir’s filings show that it is a Florida corporation with common stock listed on The Nasdaq Stock Market LLC under the symbol TELO, and they document its focus on developing Telomir-1, a small-molecule therapy targeting epigenetic and metabolic mechanisms in cancer and age-related disease.
For Telomir, Form 8‑K current reports are especially informative. Recent 8‑Ks include Item 8.01 disclosures of new preclinical data, such as Telomir-1’s effects on PSA levels in prostate cancer cells, tumor growth and metastasis in triple-negative breast cancer models, cytotoxicity in leukemia cells, and reductions in intracellular iron compared with the iron chelator Deferoxamine. Another 8‑K details completion of GLP toxicology and safety pharmacology studies in rat and dog models, noting that Telomir-1 was generally well tolerated with no treatment-related adverse or dose-limiting toxicities observed.
Filings also cover corporate and governance matters. Examples include an 8‑K describing a director resignation, compensation committee actions regarding the chief executive officer’s incentives, and a Nasdaq notice related to the timing of the company’s annual shareholder meeting under Listing Rule 5620(a). An additional 8‑K outlines a binding Letter of Intent to acquire TELI Pharmaceuticals, Inc., intended to consolidate worldwide intellectual property and development rights to Telomir-1 within a single public company structure.
On Stock Titan, these filings are supplemented by AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand the implications of GLP safety data, oncology study updates, compensation decisions, and Nasdaq communications. Users can review real-time updates from EDGAR, examine narrative descriptions of Telomir-1’s preclinical profile, and track how Telomir reports its IND-enabling activities and strategic transactions over time.
Telomir Pharmaceuticals filed an 8-K to share new preclinical data on its lead program, Telomir-Zn. A peer-reviewed paper in Biomedicine & Pharmacotherapy reports that Telomir-Zn improved glucose metabolism and insulin resistance in a diet-induced zebrafish model of Type 2 diabetes.
The study showed dose-dependent improvements in fasting blood glucose, glucose tolerance, fasting insulin, and HOMA-IR, with HOMA-IR scores falling from about 10–12 to around 3 after 14 days of treatment. The company notes this is its second Telomir-Zn publication in 2026 and says the findings further support its metal-homeostasis mechanism, which also underpins its FDA-cleared Phase 1/2 trial in advanced or metastatic triple-negative breast cancer.
Telomir Pharmaceuticals, Inc. filed an initial ownership report for Chief Financial Officer Andriy Mushak. This Form 3 shows his status as an officer but does not list any common stock or derivative security transactions or holdings at the time of the filing.
Telomir Pharmaceuticals, Inc. reported a leadership change in its finance function. Effective June 6, 2026, Alan Weichselbaum will no longer serve as Chief Financial Officer, with the company stating his departure is not due to any disagreement over operations, policies, or practices. On June 3, 2026, the board appointed Andriy Mushak, a Massachusetts-licensed CPA with over 20 years of SEC reporting and audit experience, as fractional Chief Financial Officer. Mushak will provide services through LMAM Consulting Group, LLC under a consulting agreement, for which he will receive $6,000 per month. The company notes he has no disclosable related-party relationships or transactions with current executives or directors.
Telomir Pharmaceuticals, Inc. CEO and Chairman Erez Aminov reported changes to his stock option awards. On May 21, 2026, he agreed to cancel previously granted options for 2,000,000 shares of common stock at a $2.10 exercise price and 1,960,170 shares at $5.02, both through dispositions to the issuer. In exchange, he received fully exercisable new options covering the same share amounts at a lower $1.30 exercise price, with expirations in 2036. The filing also shows he holds 7,319,710 common shares directly after these transactions, and it does not report any open‑market purchases or sales.
Telomir Pharmaceuticals director Whalen Matthew Pratt reported an option restructuring. He agreed to cancel 25,000 incentive stock options with a $5.02 exercise price in exchange for 25,000 new options with a lower $1.30 exercise price, expiring on May 21, 2036. Following these transactions, he holds 25,000 incentive stock options that are fully exercisable.
Telomir Pharmaceuticals director Edward Clouston MacPherson restructured his stock options with no net change in option count. He agreed to cancel an existing option for 25,000 shares of common stock with a $5.02 exercise price and an expiration on August 27, 2034. In exchange, he received a new option for 25,000 shares at a lower exercise price of $1.30, expiring on May 21, 2036. These are incentive stock options granted as compensation, not open-market share purchases or sales, and he now holds 25,000 options directly following the transaction.
Telomir Pharmaceuticals, Inc. director Matthew Paul Del Giudice reported a restructuring of his stock options with no net change in option count. He agreed to cancel 25,000 fully exercisable incentive stock options for common stock with a $5.02 exercise price and a August 27, 2034 expiration, as a disposition back to the issuer.
In exchange, he received a new grant of 25,000 incentive stock options for common stock with a lower exercise price of $1.30 per share and a May 21, 2036 expiration. Following these transactions, he holds 25,000 stock options directly, and no common shares were bought or sold in the market.
Telomir Pharmaceuticals, Inc. filed an 8-K describing a press release about a new peer-reviewed preclinical study of its lead candidate Telomir-1 (Telomir-Zn) in Wilson’s disease. The study, published in Advances in Redox Research, used cellular systems and an ATP7B-deficient zebrafish model.
Telomir-Zn showed dose-dependent benefits across multiple endpoints, including reduced copper-associated oxidative stress, lower hepatic copper burden, improved liver injury biomarkers such as ALT, AST and bilirubin, attenuated intracellular calcium dysregulation, better locomotor performance, reduced hepatorenal tissue degeneration, and improved survival.
This is Telomir-Zn’s first peer-reviewed publication in Wilson’s disease and adds independently validated preclinical data supporting its mechanism of modulating intracellular copper and redox pathways. The company notes these pathways are also relevant to its Telomir-Zn program in Triple-Negative Breast Cancer, which has FDA IND clearance for a Phase 1/2 trial.
Telomir Pharmaceuticals reported a Q1 2026 net loss of $0.99 million with no revenue, reflecting its early-stage biotech focus on Telomir-1 (Telomir-Zn) for cancer and age-related diseases. Operating costs were $1.04 million, with general and administrative expenses falling sharply year over year as prior stock-based compensation stepped down, while research and development rose modestly as preclinical and clinical work progressed.
Cash was $5.6 million as of March 31, 2026 after using about $1.8 million in operating cash during the quarter, leaving stockholders’ equity of roughly $5.0 million. Management states there is substantial doubt about the company’s ability to continue as a going concern over the next 12 months without new capital. After quarter-end, Telomir closed its merger with related-party TELI Pharmaceuticals, issuing 34,389,710 restricted shares and securing a $1.0 million cash contribution plus a binding commitment for up to an additional $4.0 million tied to Telomir-1 development milestones. A small at-the-market sale added about $6,000 of proceeds.
Telomir Pharmaceuticals, Inc. reported that the U.S. Food and Drug Administration has cleared its Investigational New Drug application for Telomir‑Zn, the company’s lead product candidate, to treat advanced or metastatic triple‑negative breast cancer.
The company plans a first‑in‑human Phase 1/2 trial starting in the first half of 2026, enrolling about 76 patients. Phase 1 will focus on safety, tolerability, dose‑limiting toxicities, pharmacokinetics, pharmacodynamics, and early antitumor activity to determine the recommended Phase 2 dose. Phase 2 will assess preliminary efficacy, with objective response rate as the primary endpoint and duration of response, progression‑free survival, overall survival, and safety as key secondary endpoints.
The trial will feature an extensive translational biomarker program to study epigenetic regulation, gene expression, histone modification, and telomere‑related biology, aiming to link target engagement and biomarker changes with clinical outcomes in triple‑negative breast cancer.